It was found that PDAC was a “cold” tumor with low TMB as reported in the literature (2, 3), but compared with the low risk-score, the high risk-score group still has higher TMB, such as conventional TP53 and KRAS mutation (Figures 5A, B), However, these mutations did not make the corresponding gene expression different at the transcriptome level, so it did not affect the expression of DEGs obtained by transcriptome analysis. This evidence concerns the gene KRAS and neoplasm.